ReviewThe European respiratory journal2022
The paradox of immune checkpoint inhibition re-activating tuberculosis.
Review in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 44 citations in OpenAlex.
- Th2 bias and T-cell exhaustion characterize the immunopathology of non-tuberculous mycobacterial pulmonary disease.NPJ systems biology and applications · 2026Article
- Evolution of the tuberculin skin test reveals generalisable Mtb-reactive T cell metaclones.Nature communications · 2026Article
- T cell-macrophage interactions in tuberculosis: What we've got here is failure to communicate.Journal of internal medicine · 2026Review
- NLRP3 inflammasomes at the ARDS-cancer interface: mechanisms and translational hypotheses.Frontiers in immunology · 2026Review
- Lung squamous cell carcinoma complicated with immune checkpoint inhibitor-associated active tuberculosis: a case report and literature review.Frontiers in oncology · 2026Article
- VISTA Confers Renal Protection in Murine Hemorrhage/Infection-Induced Acute Kidney Injury: Associations with Altered NGAL and HMGB1 Expression.ImmunoTargets and therapy · 2026Article
- Case Report: PD-1/CTLA-4 dual checkpoint blockade(QL1706) in advanced pulmonary squamous cell carcinoma complicated by multidrug-resistant tuberculosis after multiple lines of immunotherapy.Frontiers in oncology · 2026Review
- Review
- Association between neutrophil-lymphocyte ratio and latent tuberculosis infection in the United States: a cross-sectional study from NHANES 2011-2012.BMC infectious diseases · 2025Article
- Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Article
- TIGIT blockade improves anti-Mycobacterium tuberculosis immunity.PLoS pathogens · 2025Article
- The Role of Inflammation in the Pathogenesis of Comorbidity of Chronic Obstructive Pulmonary Disease and Pulmonary Tuberculosis.International journal of molecular sciences · 2025Review
- Leveraging insights from cancer to improve tuberculosis therapy.Trends in molecular medicine · 2025Article
- Where lung cancer and tuberculosis intersect: recent advances.Frontiers in immunology · 2025Review
- Deciphering the Correlation between the Emergence of Lung Carcinoma Associated with Tuberculosis-related Inflammation.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Regulatory Mechanisms of Co-Inhibitory Receptors in Tuberculosis Immunity: Implications for Therapeutic Targets.ImmunoTargets and therapy · 2025Review
- Impact of Latent Tuberculosis Infection and T-SPOT.TB Dynamics Alterations on Prognosis in Advanced NSCLC Treated With ICIs--IPTW-Based Retrospective Study.Clinical Medicine Insights. Oncology · 2025Article
- CD14Frontiers in cellular and infection microbiology · 2025Article
- CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications.Experimental hematology & oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
By attenuating T-cell activation, immune checkpoints (ICs) limit optimal anti-tumour responses and IC inhibition (ICI) has emerged as a new therapy for a broad range of cancers. T-cell responses are indispensable to tuberculosis (TB) immunity in humans. However, boosting T-cell immunity in cancer patients by blocking the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) axis can trigger re-activation of latent TB. This phenomenon appears to contradict the prevailing thought that enhancing T-cell immunity to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.